What should you know about myeloma cells?

Plasma cells normally help defend against infection by making antibodies. In multiple myeloma, an abnormal plasma-cell clone multiplies in the marrow. These cells may crowd out normal cells, contributing to anaemia, infection risk or bleeding problems. They can also release a single abnormal protein, sometimes called a monoclonal protein.

The abnormal cells and their signals can increase bone breakdown, leading to weakened areas or high calcium. The abnormal protein may place strain on the kidneys, while reduced normal antibody production can make infections harder to handle. Doctors assess these effects with blood and urine tests, imaging and sometimes a marrow sample.

Bring reports of infections, bone pain, tingling, unusual bruising, thirst or changes in urination to the appointment. The care team may measure blood counts, kidney function, calcium and abnormal proteins, then relate them to imaging and marrow findings. Treatment can include chemotherapy, targeted therapy, transplant, CAR T-cell therapy, radiotherapy for a focused problem and bone-strengthening therapy.

Seek urgent help for fever during treatment, severe weakness, chest pain, difficulty breathing, sudden back pain, new numbness or weakness, confusion, very little urine or persistent vomiting. These symptoms may reflect infection, nerve pressure, high calcium, kidney trouble or another emergency and should not wait for a routine review.

What do my marrow, blood, urine and imaging results show? Are the myeloma cells affecting my kidneys, bones or blood counts? Which treatment sequence is being considered? How will response and side effects be monitored?